Cinctive Capital Management Invests in Exact Sciences

Got story updates? Submit your updates here. ›

Cinctive Capital Management LP, a hedge fund, purchased a new stake of 22,614 shares in Exact Sciences Corporation (NASDAQ:EXAS) during the third quarter, according to a recent SEC filing. Exact Sciences is a molecular diagnostics company known for its Cologuard non-invasive colorectal cancer screening test.

Why it matters

Exact Sciences has seen growing investor interest as its Cologuard test gains traction in the market for colorectal cancer screening. The company's stock has risen significantly over the past year as it expands its product portfolio and research pipeline. Cinctive Capital's investment signals confidence in Exact Sciences' long-term growth potential.

The details

According to the 13F filing, Cinctive Capital Management purchased the 22,614 shares of Exact Sciences stock valued at approximately $1.2 million. Exact Sciences is a medical research company focused on early cancer detection and prevention, best known for its Cologuard stool-based DNA screening test for colorectal cancer. The company has expanded through strategic acquisitions and internal R&D in recent years.

• Cinctive Capital Management purchased the Exact Sciences shares during the third quarter of 2025.